Lobectomy with radical lymph node dissection remains the gold standard treatment for stage I primary non-small cell lung cancer (NSCLC) but in recent years, stereotaxic radiotherapy (SBRT) have gradually taken their place in this indication. The choice of doses and fractionation and the stereotactic radiotherapy technique should be considered taking into account the patient’s clinical situation and the tumour to be treated (size and topography.)Some specials clinical setting as the treatment of ground glass opacity remain questionable without a lot of evidence in scientifics publications but offer a real alternative of treatment for inoperables patients. In regards to catch-up treatments, reirradiations offer new perspectives in case of local failure after stereotactic radiotherapy with promising results. But the majority of relapses are regional or metastatic and systemic treatment especially adjuvant immunotherapy is a very interesting treatment option for this frail patients, not enough fit to receive chemotherapy.The spontaneous evolution of NSCLC lung tumors without treatment remain very negative; The use of local non-surgical treatments as SBRT is an major option for the care of elderly patients who are not eligible for surgery. Despite their comorbidities, frailty and their poor remaining survival the majority of this patients will die of their lung cancer.© 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Read full abstract